NIDCD Cooperative Agreement for Clinical Trials in Communication Disorders and NIDCD Clinical Trial Routes
National Institute on Deafness and Other Communication Disorders (NIDCD), NIH
NIDCD's own routing page for clinical trial applications, and unusually concrete about where a trial belongs. Lower-risk trials go through the NIH parent R01 announcements (PA-25-305 for clinical trial required, PA-25-303 for basic experimental studies with humans) when the trial needs no FDA oversight, carries safety risks no greater than routine medical care, is not powered to change health policy or standard of care, and is not an NIH-defined Phase III trial — generally under $500,000 annual direct costs. Higher-risk or pivotal trials go through the NIDCD-specific cooperative agreement PAR-
- Indicative award
- up to $500k per year (per year)The page gives budget thresholds that route applications, not fixed award sizes. Lower-risk trials on the parent R01 route are described as generally under $500,000 annual direct costs — recorded here as the maximum for that route. The NIDCD cooperative agreement route (PAR-25-343) is stated as able
- Timing
- Varies by programmeNo specific published date recorded. This funder publishes a cycle rather than a date, and this database does not invent one.No deadlines are published on this routing page. Each named announcement (PA-25-305, PA-25-303, PAR-25-343) carries its own receipt dates in the NIH Guide; parent PA announcements conventionally use standard recurring cycles while the PAR may differ, so read the specific announcement.
- Who can apply
- Postdoctoral, Early-career faculty, Mid-career & senior, Any faculty rank
- Eligibility
- Eligibility is set by the underlying announcements, which are institutional NIH grants: a domestic university, hospital, research institute or other eligible organisation applies and names the principal investigator. The operative gate here is not applicant type but trial risk classification — a trial requiring FDA oversight through an IND or IDE, using unlicensed products or devices, using licensed products for unapproved indications or populations, or that is pivotal or Phase III, is pushed out of the R01 route and into the NIDCD cooperative agreement. Cooperative agreements also carry subst
- SSWR clusters
- Topics
- clinical trials · behavioral intervention · communication disorders · hearing and speech · trial risk classification
- Apply at
- https://www.nidcd.nih.gov/research/clinical-studies/researchers-professionals/know-what-is-available
- This entry
- Curated by the working group. Written 2026-08-07. The funder link has not yet been machine-checked.
Amounts and dates on this page are indicative and are maintained by people rather than scraped. Funders change ceilings, windows and eligibility without notice; confirm all details at the source above before applying.
Also on the Disability shelf
- Health services research grantsAgency for Healthcare Research and QualityAmount not published · Several times a year · Feb, Jun, Oct
- Education Research GrantsInstitute of Education Sciences, U.S. Department of Education$100k–$4M · Annual cycle · Aug
- Congressionally Directed Medical Research ProgramsU.S. Department of DefenseAmount not published · Annual cycle · Apr, May, Jun, Jul
- Disability and aging research and demonstration grantsAdministration for Community Living$200k–$4M · Annual cycle
- Patient-centered outcomes research fundingPatient-Centered Outcomes Research Institute$500k–$10M · Several times a year · Jan, May, Sep
- Grants in aging and serious illness careThe John A. Hartford Foundation$250k–$3M · By invitation